Unknown

Dataset Information

0

Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.


ABSTRACT: Blinded clinical trials have reported a modest and transient "start-up syndrome" with initiation of tenofovir-based pre-exposure prophylaxis (PrEP). We evaluate this phenomenon and its effect on adherence in an open-label PrEP study.In the iPrEx open-label extension (OLE) study, an 18-month open-label, multi-site PrEP cohort taking daily oral co-formulated tenofovir/emtricitabine, we examined the prevalence and duration of PrEP-associated symptoms and their effect on adherence, assessed by drug levels in dried blood spots tested monthly for the first 3 months.Symptom reports peaked within the first month, with 39% reporting potentially PrEP-related symptoms compared to 22% at baseline. Symptoms largely resolved to pre-PrEP levels by 3 months.Symptoms varied substantially in frequency by study site (range in 1-month symptoms: 11% to 70%). Nongastrointestinal (GI) symptoms were not associated with adherence (odds ratio [OR] = 1.2, 95% confidence interval [CI], .4-3.7); however, GI-associated symptoms in the first 4 weeks were inversely associated with adherence at 4 weeks (OR = 0.47, 95% CI, .23-.96). Reports of GI symptoms were associated with 7% (95% CI, 4%-11%) of suboptimal adherence in this cohort.PrEP-associated symptoms in the open-label setting occur in a minority of users and largely resolve within 3 months. GI symptoms are associated with a modest reduction in PrEP adherence, but good adherence is possible even in the presence of frequent symptom reports.Clinicaltrials.govNCT00458393.

SUBMITTER: Glidden DV 

PROVIDER: S-EPMC4826449 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4601920 | BioStudies
2017-01-01 | S-EPMC5681370 | BioStudies
2019-01-01 | S-EPMC6417801 | BioStudies
2014-01-01 | S-EPMC4059553 | BioStudies
2018-01-01 | S-EPMC6061961 | BioStudies
2014-01-01 | S-EPMC4191829 | BioStudies
2014-01-01 | S-EPMC4229454 | BioStudies
2019-01-01 | S-EPMC6701758 | BioStudies
2013-01-01 | S-EPMC3559346 | BioStudies
2019-01-01 | S-EPMC6742570 | BioStudies